The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.
Vaccines, Blood & Biologics
June 30, 2011 Approval Letter - FluLaval 2011/2012 Forumation
Our STN: BL 125163/204
ID Biomedical Corporation of Quebec
Attention: LaDonna Nugent, M.S.
2301 Renaissance Boulevard
Building 510, P.O. Box 61540
King of Prussia, PA 19406-2772
Dear Ms. Nugent:
We have approved your request to supplement your biologics license application for Influenza Virus Vaccine (FluLaval®), to include the 2011-2012 United States formulation.
Please submit all final printed labeling at the time of use and include implementation information on Form FDA 356h. Please provide your final content of labeling in Structured Product Labeling (SPL) format and include the carton and container labels.
We will include information contained in the above-referenced supplement in your biologics license application file.
Jerry P. Weir, Ph.D.
Division of Viral Products
Office of Vaccines
Research and Review
Center for Biologics
Evaluation and Research